(1-氧代酞嗪-2(1H)-基)乙酸 | 90689-39-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: (1-氧代酞嗪-2(1H)-基)乙酸
• 中文别名: （1-氧邻酞嗪-2（1H）-基）乙酸
• 英文名称: [1(1H)-phthalazinon-2-yl]acetic acid
• 英文别名: (3,4-dihydro-4-oxophthalizin-3-yl)acetic acid；1(2H)-oxophthalazine-2-acetic acid；2-(1-oxophthalazin-2(1H)-yl)acetic acid；(1-oxophthalazin-2(1H)-yl)acetic acid；2-(1-oxophthalazin-2-yl)acetic acid
• CAS: 90689-39-7
• 化学式: C₁₀H₈N₂O₃
• mdl: MFCD04035514
• 分子量: 204.185
• InChiKey: GXRUGARSVAZFHT-UHFFFAOYSA-N

物化性质

• 熔点：
  227-228 °C(Solv: methanol (67-56-1))
• 沸点：
  444.6±47.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)
• 溶解度：
  27.8 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  70
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (1-氧代酞嗪-2(1H)-基)乙酸 在 potassium carbonate 作用下， 以 乙醇 为溶剂， 反应 0.25h， 生成 3-[(1(2H)-oxophthalazin-2-yl)methyl]-6-methyl-7H-s-triazolo[3,4-b][1,3,4]thiadiazine
  参考文献：
  名称：

  杂环合成中的酞嗪酮：合成 Somes-三唑、s-三唑噻二嗪、s-三唑噻二嗪和 s-三唑噻二唑衍生物作为药用

  摘要：

  1(2H)-Oxophthalazine-2-乙酸乙酯在不同条件下与各种试剂反应，得到化合物2-[(4-取代-5-巯基三唑-3-基)甲基]-1(2H)-氧代酞嗪 5 和 7 用作制备一些新型 s-三唑并[5,1-b][1,3]噻嗪 (8)、s-三唑并[3,4-b][1,3, 4]噻二嗪9,12,14,20和s-三唑并[3,4-b][1,3,4]噻二唑18,21衍生物。作者衷心感谢埃及开罗国家研究中心天然和微生物产品部 Ahmed A. El-Beih 博士提供的抗菌数据。

  DOI：

  10.1080/10426500390228666
• 作为产物：
  描述：

  1(2H)-oxophthalazin-2-acetic acid ethyl ester 在 盐酸 作用下， 反应 2.0h， 以80%的产率得到(1-氧代酞嗪-2(1H)-基)乙酸
  参考文献：
  名称：

  杂环合成中的酞嗪酮：合成 Somes-三唑、s-三唑噻二嗪、s-三唑噻二嗪和 s-三唑噻二唑衍生物作为药用

  摘要：

  1(2H)-Oxophthalazine-2-乙酸乙酯在不同条件下与各种试剂反应，得到化合物2-[(4-取代-5-巯基三唑-3-基)甲基]-1(2H)-氧代酞嗪 5 和 7 用作制备一些新型 s-三唑并[5,1-b][1,3]噻嗪 (8)、s-三唑并[3,4-b][1,3, 4]噻二嗪9,12,14,20和s-三唑并[3,4-b][1,3,4]噻二唑18,21衍生物。作者衷心感谢埃及开罗国家研究中心天然和微生物产品部 Ahmed A. El-Beih 博士提供的抗菌数据。

  DOI：

  10.1080/10426500390228666

文献信息

• Synthesis of New 2-[1(2H)-Phthalazinon-2-yl]acetamide and 3-[1(2H)-Phthalazinon-2-yl]propanamide Derivatives as Antinociceptive and Anti-inflammatory Agents
  作者：Deniz S. Dogruer、Esra Kupeli、Erdem Yesilada、M. Fethi Sahin

  DOI：10.1002/ardp.200200719

  日期：2004.6

  ongoing studies on heterocyclic compounds for new antinociceptive and anti‐inflammatory agents bearing lactam functional group, new 2‐[1(2H)‐phthalazinon‐2‐yl]acetamide and 3‐[1(2H)‐phthalazinon‐2‐yl]propanamide derivatives have been synthesized. Among the compounds synthesized, compound 4e was found the most active derivative in terms of antinociceptive and anti‐inflammatory activities, without gastric

  由于我们正在进行对杂环化合物的研究，这些化合物用于具有内酰胺官能团的新型镇痛和抗炎剂、新型 2-[1 (2H)-酞嗪酮-2-基]乙酰胺和 3-[1 (2H)-酞嗪酮-已经合成了2-基]丙酰胺衍生物。在合成的化合物中，发现化合物 4e 在镇痛和抗炎活性方面是最活跃的衍生物，在给定剂量下没有胃损伤和出血。
• Rhodium(III)-Catalyzed C–H Functionalization of 1-(2<i>H</i>)-Phthalazinones at C8
  作者：Malcolm P. Huestis

  DOI：10.1021/acs.joc.6b02522

  日期：2016.12.16

  The rhodium(III) catalyst tris(acetonitrile)pentamethylcyclopentadienylrhodium(III) hexafluoroantimonate ([Cp*Rh(MeCN)3](SbF6)2) reacts with 1-(2H)-phthalazinones to promote a C–H functionalization event at C8. Preparation of a set of compounds arising from oxidative alkenylation with olefins, hydroarylation with alkynes, and iodination with N-iodosuccinimide is reported here. Oxidative alkenylation

  铑（III）催化剂六氟锑酸三（乙腈）五甲基环戊二烯基铑（III）（[Cp * Rh（MeCN）3 ]（SbF 6）2）与1-（2 H）-邻苯二氮酮反应以促进C H功能化事件的发生C8。在此报道了一组由烯烃的氧化烯基化，与炔烃的加氢芳基化以及与N-碘代琥珀酰亚胺的碘化反应产生的化合物的制备。氧化烯基化反应的收率很高，并讨论了氢化芳基化和卤化反应的范围和局限性。值得注意的是，该策略能够快速制备C8取代的邻苯二氮酮，而无需从预官能化的芳烃开始合成邻苯二氮酮环。
• Annulation to the phthalazine ring system utilizing mesoionic ring systems
  作者：Kevin T. Potts、Kirk G. Bordeaux、William R. Kuehnling、Ronald L. Salsbury

  DOI：10.1021/jo00210a022

  日期：1985.5
• POTTS, K. T.;BORDEAUX, K. G.;KUEHNLING, W. R.;SALSBURY, R. L., J. ORG. CHEM., 1985, 50, N 10, 1677-1681
  作者：POTTS, K. T.、BORDEAUX, K. G.、KUEHNLING, W. R.、SALSBURY, R. L.

  DOI：——

  日期：——
• [EN] DNA-ENCODED CHEMICAL LIBRARIES<br/>[FR] BIBLIOTHÈQUES DE PRODUITS CHIMIQUES CODÉS PAR ADN
  申请人：PHILOCHEM AG

  公开号：WO2009077173A2

  公开（公告）日：2009-06-25

  A method of preparing a DNA-encoded chemical library comprising members which comprise a chemical moiety, a linking moiety and a DNA moiety, comprising for each member the steps of: (I) coupling a initial building block to a initial coding single strand oligomer via a linking moiety to form a initial conjugate, the initial coding single strand oligomer comprising a first primer region, an initial coding region and a first annealing region; (II) optionally coupling a middle building block and middle coding single strand oligomer to said initial conjugate to form a middle conjugate, the coupling take place in either order, wherein: (a) the middle building block is coupled to the residue of the initial building block; and (b) the middle coding single strand oligomer comprises a middle coding region and second annealing region, and is coupled by: (i) annealing a complementary single strand oligomer which comprises a chemical modifier, a complementary first annealing region, a complementary middle coding region and a complementary second annealing region by interaction between the first annealing region and the complementary first annealing region; (ii) treating the conjugate formed with a DNA polymerase to elongate the initial coding single strand oligomer to be complementary to the complementary middle coding region and the complementary second annealing region; (iii) removing the complementary single strand oligomer by denaturing the DNA and capturing the complementary single strand oligomer via the chemical modifier; (III) coupling a final building block and final coding single strand oligomer to the initial or middle conjugate as appropriate to form a final conjugate, the coupling take place in either order, wherein: (a) the final building block is coupled to the residue of the initial building block, or may be additionally or alternatively be coupled to the residue of the middle building block (if present); and (b) the final coding single strand oligomer comprises a final coding region and a second primer region, and is coupled by: (i) annealing a complementary single strand oligomer which comprises a complementary first or second annealing region as appropriate, a complementary final coding region and a complementary second primer region, by interaction between the first or second annealing region and the complementary first or second annealing region, as appropriate; (ii) treating the conjugate formed with a DNA polymerase to elongate the initial coding single strand oligomer to be complementary to the complementary final coding region and the complementary second primer region, and to elongate the complementary coding strand to be complementary to the initial coding single strand oligomer.